Drug Counterfeiting List To Be Released By Boards Of Pharmacy Feb. 27
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA has yet to create its own list of problem products. NABP hopes its document will become a national reference.
You may also be interested in...
Drug Radio Frequency ID To Be Widespread By 2007, FDA's McClellan Says
FDA expects the anticounterfeit technology will be implemented over a phased-in timeline. Although the agency does not plan to require use, it will take an active role in facilitating adoption of RFID.
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.
User Fee Deal For Ad Review Funds Stems From PhRMA DTC Principles
A draft agreement between industry and FDA that would assess user fees for "advisory review" of broadcast direct-to-consumer ads prior to initial public dissemination had its genesis in the Pharmaceutical Research & Manufacturers of America's DTC guiding principles